3SBio

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

In what Merck describes as “early signs of promising anti-tumor activity,” the PD-1xVEGF bispecific, coded MK-2010, induced an unconfirmed ORR of 55%.

Angus Liu Apr 17, 2026 3:00pm

Pfizer lays out its PD-1xVEGF bispecific research strategy

Nov 11, 2025 11:43am

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific

May 20, 2025 4:47am

Vasella helps Numab to CHF22M round ahead of cancer trial start

Mar 9, 2020 7:00am

Verseau bags $50M for cancer R&D, names Golumbeski as chairman

Oct 21, 2019 12:05am

Refuge Biotech scores $25M from Chinese backers for CAR-T

May 2, 2018 10:49am